Common chemicals acting together may be carcinogenic to humans
the ONA take:
Common chemicals not considered to be carcinogenic to humans at low doses may act together to increase cancer risk, according a 3-year investigation conducted by a task force comprised of nearly 200 researchers from 28 countries.
Of the 85 chemicals studied, 50 were found to disrupt normal cell function in ways that are known to be associated with early signs of cancer.
Chemicals studied included bisphenol A (BPA), a chemical used in plastics, rotenone, an insecticide, paraquat, a herbicide, triclosan, an antibacterial agent, and EDTA, a metal-ion-binding compound used in manufacturing and medicine.
"Our findings also suggest these molecules may be acting in synergy to increase cancer activity," said William Bisson, an assistant professor and cancer researcher at OSU and a team leader on the study.
EDTA alone does not cause gene mutations, but when exposed to that and something else that is mutagenic, the effect of DNA repair disruption is enhanced.
The findings suggest that more research is warranted to evaluate early exposure to these common chemicals and how those chemicals affect the early stages of cancer development.
Common chemicals not considered to be carcinogenic to humans at low doses may act together to increase cancer risk.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|